Advertisement
Australia markets close in 4 hours 19 minutes

  • ALL ORDS

    7,948.30
    +10.40 (+0.13%)
     

  • ASX 200

    7,693.70
    +10.20 (+0.13%)
     

  • AUD/USD

    0.6522
    +0.0033 (+0.50%)
     

  • OIL

    83.31
    -0.05 (-0.06%)
     

  • GOLD

    2,331.50
    -10.60 (-0.45%)
     

  • Bitcoin AUD

    102,458.25
    -150.62 (-0.15%)
     

  • CMC Crypto 200

    1,435.99
    +21.23 (+1.50%)
     

  • AUD/EUR

    0.6085
    +0.0029 (+0.48%)
     

  • AUD/NZD

    1.0979
    +0.0049 (+0.45%)
     

  • NZX 50

    11,861.80
    +58.52 (+0.50%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,973.05
    +144.12 (+0.86%)
     

  • NIKKEI 225

    38,256.71
    +704.55 (+1.88%)
     

Why Sanofi May Be a Frontrunner in Endemic COVID-19

Natalie Forbes, The Motley Fool
·4-min read
Why Sanofi May Be a Frontrunner in Endemic COVID-19

Global biopharmaceutical company Sanofi (NASDAQ: SNY) encountered setbacks while developing its COVID-19 vaccine, and only this year reported results from late-stage clinical trials. Sanofi opted for the more traditional protein-based technology for its COVID-19 vaccine, Vidprevtyn, rather than the mRNA technology of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax. The mRNA technology delivers genetic code instructing the body's cells to make the protein, while the more traditional approach produces the protein in a lab before injecting it into the body.

Continue reading